Artemis Investment Management LLP Sells 27,608 Shares of Intuitive Surgical, Inc. (NASDAQ:ISRG)

Artemis Investment Management LLP trimmed its holdings in Intuitive Surgical, Inc. (NASDAQ:ISRG) by 22.9% in the 3rd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 92,977 shares of the medical equipment provider’s stock after selling 27,608 shares during the period. Artemis Investment Management LLP’s holdings in Intuitive Surgical were worth $45,677,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. One Wealth Management Investment & Advisory Services LLC lifted its stake in shares of Intuitive Surgical by 3.4% in the second quarter. One Wealth Management Investment & Advisory Services LLC now owns 697 shares of the medical equipment provider’s stock worth $310,000 after buying an additional 23 shares during the last quarter. Indiana Trust & Investment Management CO lifted its position in Intuitive Surgical by 5.3% during the 2nd quarter. Indiana Trust & Investment Management CO now owns 500 shares of the medical equipment provider’s stock worth $222,000 after acquiring an additional 25 shares during the last quarter. Hoxton Planning & Management LLC boosted its holdings in Intuitive Surgical by 4.9% during the second quarter. Hoxton Planning & Management LLC now owns 534 shares of the medical equipment provider’s stock valued at $238,000 after acquiring an additional 25 shares during the period. First Affirmative Financial Network grew its position in shares of Intuitive Surgical by 2.7% in the second quarter. First Affirmative Financial Network now owns 996 shares of the medical equipment provider’s stock valued at $443,000 after purchasing an additional 26 shares during the last quarter. Finally, Moors & Cabot Inc. increased its stake in shares of Intuitive Surgical by 2.3% in the second quarter. Moors & Cabot Inc. now owns 1,159 shares of the medical equipment provider’s stock worth $516,000 after purchasing an additional 26 shares during the period. Institutional investors and hedge funds own 83.64% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on ISRG. Stifel Nicolaus increased their target price on Intuitive Surgical from $430.00 to $475.00 and gave the company a “buy” rating in a research note on Friday, July 19th. Evercore ISI raised their price objective on shares of Intuitive Surgical from $410.00 to $475.00 and gave the stock an “in-line” rating in a research note on Tuesday, October 1st. Robert W. Baird upped their target price on shares of Intuitive Surgical from $487.00 to $503.00 and gave the company an “outperform” rating in a research note on Friday, July 19th. Truist Financial increased their price target on shares of Intuitive Surgical from $450.00 to $515.00 and gave the company a “buy” rating in a report on Tuesday, July 16th. Finally, BTIG Research boosted their price objective on shares of Intuitive Surgical from $469.00 to $494.00 and gave the stock a “buy” rating in a report on Wednesday, August 28th. Six research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $454.35.

Intuitive Surgical Stock Up 2.0 %

Shares of ISRG stock opened at $480.79 on Wednesday. The company has a market capitalization of $170.53 billion, a P/E ratio of 86.78, a P/E/G ratio of 5.39 and a beta of 1.39. Intuitive Surgical, Inc. has a 12-month low of $254.85 and a 12-month high of $496.48. The firm has a 50-day moving average price of $477.10 and a 200 day moving average price of $432.68.

Intuitive Surgical (NASDAQ:ISRG) last announced its earnings results on Thursday, July 18th. The medical equipment provider reported $1.78 EPS for the quarter, topping the consensus estimate of $1.54 by $0.24. Intuitive Surgical had a return on equity of 13.04% and a net margin of 27.65%. The business had revenue of $2.01 billion for the quarter, compared to the consensus estimate of $1.97 billion. During the same period in the previous year, the business earned $1.18 EPS. Intuitive Surgical’s revenue was up 14.5% compared to the same quarter last year. As a group, research analysts expect that Intuitive Surgical, Inc. will post 5.22 earnings per share for the current year.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, Director Craig H. Barratt sold 1,400 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $641,382.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other news, EVP Myriam Curet sold 2,818 shares of the firm’s stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $458.13, for a total value of $1,291,010.34. Following the transaction, the executive vice president now owns 298 shares of the company’s stock, valued at approximately $136,522.74. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Craig H. Barratt sold 1,400 shares of Intuitive Surgical stock in a transaction that occurred on Tuesday, July 23rd. The stock was sold at an average price of $458.13, for a total transaction of $641,382.00. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 53,120 shares of company stock worth $25,528,753. Insiders own 0.90% of the company’s stock.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.